Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis

Haematologica

Volumn 91, Issue 12, 2006, Pages 1635-1643

  Perfetti, Vittorio ^a,b   Siena, Salvatore ^d   Palladini, Giovanni ^a   Bregni, Marco ^d   Di Nicola, Massimo ^d   Obici, Laura ^a   Magni, Michele ^d   Brunetti, Laura ^b   Gianni, Alessandro Massimo ^d   Merlini, Giampaolo ^a,c  

^a Amyloid Center   (Italy)

^b Internal Medicine and Medical Oncology Department

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

AL amyloidosis; Autologous peripheral blood transplantation; Primary amyloidosis

Indexed keywords

ATROPINE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; MUCOSA INFLAMMATION; PERIPHERAL EDEMA; REMISSION; RISK FACTOR; SEPSIS; SHOCK; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AMYLOIDOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELPHALAN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RISK FACTORS; SURVIVAL ANALYSIS; TIME; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 33845929988     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
2. Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, et al. Analysis of V(λ)-J(λ) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (λIII) as a new amyloid-associated germline gene segment. Blood 2002;100:948-53.
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.
4. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 2005;36:597-600.
5. Merlini G. AL amyloidosis:therapeutic strategies 2004. Hematology (Am Soc Hematol Educ Program) 2004;261-9.
6. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82.
7. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998;101:766-9.
8. Perfetti V, Garini P, Vignarelli MC, Marinone MG, Zorzoli I, Merlini G. Diagnostic approach to and follow-up of difficult cases of AL amyloidosis. Haematologica 1995;80:409-15.
9. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11-22.
10. th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-28.
11. Kumar S, Dispenzieri A, Lacy MQ, Litzow MR, Gertz MA. High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 2001;28:381-5.
12. Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005;35:567-75.
13. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
14. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 2002;113:549-55.
15. Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A, et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999;24:853-5.
16. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 2001;19:3350-6.
17. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960-3.
18. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004;103:2936-8.
19. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
20. Jaccard A, Moreau A, Leblond V, Leleu X, Benboubker L, Hermine O, et al. Autologous stem cell transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloidosis: results of the french multicentric randomized trial (MAG and IFM Intergroup). Blood 2005;106[Abstract421].
21. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.
22. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7.
23. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Prognostication of survival using cardiac troponins and N-terminal probrain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-7.
24. Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, et al. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate. Bone Marrow Transplant 2004;34:1025-31.
25. Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Gerda S, et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999;104:553-9.
26. Dhodapkar MV, Hussein MA, Rasmussen E, Solomon A, Larson RA, Crowley JJ, et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004;104:3520-6.
27. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005;105:2949-51.